Molecular Probes Inc. Monsanto

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information

Molecular Probes Inc.

P.O. Box 22010, 29851 Willow Creek Road Eugene OR 97402-0469, US Phone: (541) 465-8300; Fax: (541) 335-0504 Toll-free phone: (800) 438-2209 (orders only) Web: www.probes.invitrogen.com E-mail: [email protected]

KEY PERSONNEL: August Sick; General Manager

EMPLOYEES: 160 employees

HISTORY: Founded in 1975 Acquired by Invitrogen Corp. (8/03)

STOCK-FINANCIAL HISTORY: Privately held

SUBSIDIARIES/DIVISIONS: Molecular Probes Europe BV--wholly owned subsidiary located in the Netherlands

SUBSIDIARY OF: Invitrogen Corp. (see separate entry)

BUSINESS STRATEGY: Be the leading provider of fluorescence-based detection solutions to advance scientific and biomedical research

PRODUCTS ON MARKET: Over 3,000 fluorescent probes for bioscience research listed in the 'Handbook of Fluorescent Probes and Research Chemicals' including Calcium Green™, Live/Dead® viability/cytotoxicity kits, SYBR® Green nucleic acid gel stain, SYPRO® Protein gel stain, FluoSpheres®, Cascade Blue®, Toto®-1, Yoyo®-1 and Bodipy®

Monsanto Co.

800 North Lindbergh Boulevard St. Louis MO 63167, US Phone: (314) 694-1000; Fax: (314) 694-4228 Web: www.monsanto.com E-mail: [email protected]

KEY PERSONNEL: Hugh Grant; Chairman, President and CEO Terrell K. Crews; Exec. VP and CFO Dr. Robert T. Fraley; Exec. VP and CTO Charles W. Burson; Exec. VP, Secretary and General Counsel Carl M. Casale; Exec. VP, North America Commercial Brett D. Begemann; Exec. VP, International Commercial Robert A. Paley; VP and Treasurer Mark J. Leidy; Exec. VP, Manufacturing Gerald A. Steiner; Exec. VP, Commercial Acceptance Steven C. Mizell; Sr. VP, Human Resources Cheryl Morley; Sr. VP, Corporate Strategy Richard B. Clark; VP and Controller Janet M. Holloway; VP and Chief of Staff Scarlett Lee Foster; VP, Investor Relations

EMPLOYEES: 22,000 employees

HISTORY: Founded in 1901 Agricultural division established (1960) Began biotech R&D in 1979 Acquired the Jacob Hartz Seed Co. (1982) Acquired 49% of Calgene Inc. (3/96) Acquired Agracetus (7/96) Increased ownership of Calgene Inc. to 54.6% through purchase of 6.25M shares (8/96)

Acquired Asgrow agronomics seed business (1997) Acquired Holden's Foundation Seeds Inc., Corn States Hybrid Service Inc. and Corn States International Sarl for up to $1b (1/97) Acquired remaining shares of Calgene for $8/share, $240M (7/97) Monsanto split into two companies--Monsanto Co. (life sciences, agriculture, health and food products) and Solutia Inc. (chemicals and fibers) (9/97) Announced plans to acquire remaining shares of Dekalb Genetics Corp. for $2.5b and Delta & Pine Land Co. for an undisclosed amount (5/98) American Home Products Corp. (now Wyeth) and Monsanto Co. announced plans to merge for $33b in stock and to create new company (6/98) Announced plans to acquire Cargill's international seed operations in Central and Latin America, Europe, Asia and Africa for $1.4b (6/98) Merged with Pharmacia & Upjohn to form Pharmacia Corp. Monsanto is the acknowledged agricultural subsidiary and will retain its name, while Pharmacia owns 85% of Monsanto. The business became a separate legal entity with a stand-alone board of directors and its own publicly traded stock. (4/00) Divested by Pharmacia Corp. in lieu of Pharmacia's merger into Pfizer Inc. (4/03) Formed American Seeds Inc. (ASI) (2004) ASI acquired Channel Bio Corp. (including three seed brands: Crows Hybrid Corn, Midwest Seed Genetics and Wilson Seeds) (2004) Acquired North American canola seed assets of Advanta Seeds from Advanta BV (9/04) Acquired the Stoneville cotton business (including its NexGen brand) (2005) ASI subsidiary acquired NC+ Hybrids Inc. (2005) ASI acquired Fontanelle Hybrids, Stewart Seeds, Trelay Seeds and Stone Seeds (2005) ASI acquired Specialty Hybrids (2005) Acquired agricultural genomics assets of Icoria Inc. (3/05) Acquired Seminis Inc. (3/05) Acquired Emergent Genetics Inc. (4/05) Sold Monsanto Enviro-Chem Systems Inc. (8/05) ASI acquired the seed marketing and sales businesses of Diener Seeds and and Sieben Hybrids (6/06) ASI to acquire Kruger Seed Co. Trisler Seed Farms and the seed marketing and sales business of Campbell Seed (as of 6/06) To acquire Delta and Pine Land Co. for $1.5b (as of 8/06) Member--Biotechnology Industry Organization

FACILITIES: Manufacturing facilities, laboratories, seed production and other agricultural facilities, office space, warehouses and other land parcels in North America, South America, Europe, Asia, Australia and Africa Seed conditioning plants at Bellary, India; Constantine, Mich.; Eluru, India; Grinnell, Iowa; Kearney, Neb.; Oxnard, Calif.; Peyehorade, France; Phitsanoluk, Thailand; Trebes, France; Uberlandia, Brazil; and Villagran, Mexico Chemicals manufacturing facilities at Alvin, Texas; Antwerp, Belgium; Augusta, Ga.; Camacari, Brazil; Luling, La.; Muscatine, Iowa; Sao Jose dos Campos, Brazil; Soda Springs, Idaho; and Zarate, Argentina

STOCK-FINANCIAL HISTORY: NYSE--MON Net sales $6.294b (YE 05) compared to $5.423b (YE 04) Net income $255M (YE 05) compared to $267M (YE 04) Earnings per share $0.94/share (YE 05) compared to $0.99/share (YE 04) Average shares outstanding 266.8M (YE 05) compared to 264.4M (YE 04)

SUBSIDIARIES/DIVISIONS: Two business segments: Seeds and Genomics (global seeds and traits businesses and genetic technology platforms) Agricultural Productivity (crop protection products, animal agriculture businesses and lawn-and-garden herbicide products)

INVESTMENTS: The Liposome Co. Target Therapeutics HybriTech Seed Europe-SNC--joint venture with CACBA Calgene Inc.--100%

Joint venture with Cargill to use biotechnology to improve feed for pigs, cattle, poultry and fish (5/98) Formed American Seeds Inc. (ASI), a holding company to support regional seed businesses (11/04)

BUSINESS STRATEGY: Produce leading seed brands and develop biotechnology traits that assist farmers in controlling insects and weeds Provide other seed companies with genetic material and biotechnology traits for their seed brands Provide lawn-and-garden herbicide products for the residential market Provide animal agricultural products focused on improving dairy cow productivity and swine genetics

AGREEMENTS: Name Products Content of Agreement Date Genaissance to map single nucleotide research agreement 3/05 Pharmaceuticals polymorphism (SNP) Inc. and the DNA markers in Agricultural soybeans Research Service (part of USDA) Agracetus Inc. transgenic cotton purchased all plant 4/96 technology biotech assets from W.R. Grace & Co Arcadia development and licensing agreement 9/05 Biosciences Inc. commercialization of Arcadia's nitrogen use efficiency technology in canola ArQule Inc. agrochemicals development 12/96 agreement Calgene Inc. fresh produce and plant R&D agreement 10/95 oils Calgene Inc. oilseed research cross-licensing 5/96 programs agreement-- Calgene will receive royalty-free license to current and future Monsanto agronomic technology in combination with Calgene's oils modification genes. Monsanto will pay Calgene royalties and $17M and will receive portion of profits of Calgene's specialty oils business Calgene Inc. patented technologies cross-licensing 4/93 agreements-- Monsanto received licenses to Calgene's patents and patents pending in the areas of plant transformation, certain genetically engineered plants, and antisense RNA technology. Calgene received licenses to

Monsanto's patents and patents pending in the areas of plant transformation technologies, selectable markers, and the right to obtain certain licenses to Monsanto's Bt insect resistance technology for use in cotton

Calgene Inc. Russet Burbank development potatoes genetically agreement modified to resist potato viruses X and Y California Institute instrument design development of Technology agreement Columbia patented rDNA nonexclusive University extraction process licensing agreement Dekalb Genetics field crops, seeds, R&D collaboration 2/96 Corp. produce and cross-licensing agreement Delta and Pine Bollard gene for marketing 11/95 Land Co. selected varieties of agreement cotton Divergence Inc. nematode-resistant development and 9/04 soybeans licensing agreement Dow new technology options global business 1/06 AgroSciences LLC and more choice in agreement products for farmers Dyax Corp. Dyax's phage display non-exclusive 5/97 technology licensing agreement, including signing fees, milestone payments and royalties, Dyax gets access to related patented technology owned by licensee Ecogen Inc. Bt technology for in- development 1/96 plant applications agreement Finnfeeds feed microingredients joint venture for for 4/98 production and marketing of feed microingredients in plants GeneTrace Inc. plant and animal $17M technology 4/98 genomics collaboration-- Monsanto gets exclusive license to GeneTrace's technology for plant and animal genomics, including gene-expression analysis and genotyping

Incyte Incyte's gene 3-year, large-scale, 5/98 Pharmaceuticals expression microarray genome-wide Inc. technology for agreement-- functional genomics Monsanto gets applications in plant, access to up to 50K animal and human DNA microarrays genomes for use across its life science programs, Incyte will provide data from custom and prefabricated DNA microarrays, software to manage and analyze data and consulting services

Incyte Incyte's LifeTools broad-based 10/97 Pharmaceuticals software and plant genomics and Inc. sequences software licensing agreement (9/96), expanded to include LifeSeq®, LifeSeq FL®, LifeSeq Atlas™, LifeSeq GeneAlbum™ cDNA, PathoSeq™ and ZooSeq™ Japan Tobacco high-yield rice joint development 12/95 Inc. agreement Mendel Monsanto to partnership, 1997 Biotechnology Inc. commercialize expanded and technologies developed extended through by Mendel, both 2011 (7/06) companies will develop an integrated framework for predictive control of plant gene expression Mexican Ministry genetically engineered R&D agreement 7/93 of Agriculture and potato to resist viral Water Resources diseases Millennium Millennium's genomics 5-year, $218M 10/97 Pharmaceuticals technology platform to agreement-- Inc. develop agricultural Monsanto to pay products $118M in licensing and technology transfer fees ($38M up-front, $16M per year for five years), Monsanto could pay an additional $20M/year in milestone payments based on research objectives, Monsanto to form subsidiary in Cambridge, MA with 100 scientists, Millennium retains right to use technologies developed by the subsidiary for non-

exclusive use outside of plant and agricultural areas Mitsubishi Kasei rDNA and MAbs joint R&D venture in Corp. Japan Modular Genetics advancement of three-year 3/05 Inc. Monsanto's protein collaboration optimization platform Molecular BioMerge software for three-year licensing 1/97 Informatics Inc. analysis of genomic agreement data North Carolina genetically engineered licensing 4/93 State University nematicides agreement-- Monsanto to develop the technology in major agricultural crops in developed countries

Pioneer Hi-Bred YieldGard insect- licensing agreement 12/95 International Inc. protected Bt corn Sandia National alignment of Sandia's three-year research 8/06 Laboratories capabilities in collaboration bioanalytical imaging and analysis with Monsanto's research in the development of seed-based products, including corn products that may be able to produce more ethanol per bushel Sandoz Seeds insect-protected Bt corn nonexclusive 8/95 Ltd. worldwide license to Monsanto patents Strategic GeneCheck R&D and Diagnostics Inc. manufacturing agreement Synteni Inc. gene expression in development 6/96 plants and organisms agreement Targeted Growth development and licensing agreement 9/05 Inc. (TGI) commercialization of a TGI-developed yield enhancement gene The Solae Co. soy proteins development and 10/05 marketing agreement

RESEARCH & DEVELOPMENT: Insect-protected corn and cotton Soybeans, canola, cotton, and corn genetically modified to tolerate Roundup® herbicide Virus- and insect-protected potatoes Delayed ripening tomatoes Cholesterol oxidase gene to protect cotton, corn, and potato plants from weevils, worms, and beetles

PRODUCTS ON MARKET: Seeds and Genomics: Roundup Ready traits in soybeans, corn, canola and cotton Bollgard and Bollgard II traits in cotton YieldGard Corn Borer and YieldGard Rootworm traits in corn Agroceres, Asgrow, Dekald, Stoneville and Vistive branded seeds Holden’s Foundation Seeds Monsoy foundation seed American Seeds Inc. branded seed Seminis, Royal Sluis, Asgrow and Petoseed branded seeds

Agricultural Productivity: Roundup and other glyphosate-based herbicides Harness, Degree, Lasso, Machete and other acetanilide-based herbicides Other selective herbicides, such as Maverick, Certainty, Outrider, Leader and Monitor sulfosulfuron herbicides Lawn-and-garden herbicides Posilac bovine somatotropin Monsanto Choice Genetics genetics lines

Morishita Jintan Co. Ltd.

1-30, Tamatsukuri 1-chome, Chuo-ku Osaka, Japan Phone: +81 6-6761-1131; Fax: +81 6-6768-1661 Web: www.jintanworld.com E-mail: [email protected]

KEY PERSONNEL: Yukihisa Aibara; President and CEO

EMPLOYEES: 300 employees

HISTORY: Founded in February 1893

STOCK-FINANCIAL HISTORY: Listed on the Tokyo and Osaka stock exchanges

SUBSIDIARIES/DIVISIONS: Branches in Shizuoka, Kagawa, Toyama and Shiga Pref.

BUSINESS STRATEGY: Develop and sell health foods, medical supplies, unregulated drugs and cosmetics based on Chinese medicines and encapsulation technology for seamless capsules

PRODUCTS ON MARKET: Pharmaceuticals: Bifina Constipation, Solmiran Health foods and dietary supplements

M-Scan Ltd.

3 Millars Business Centre, Fishponds Close Wokingham RG41 2TZ, UK Phone: +44 (0)118 989 6940; Fax: +44 (0)118 989 6941 Web: www.m-scan.com E-mail: [email protected]

KEY PERSONNEL: Prof. H. R. Morris; Chairman Dr. Fiona M. Greer; Director Dr. Andrew Reason; Director Dr. C. Harbach; Sr. Scientist Dr. David Chapman; Business Manager

EMPLOYEES: 28 employees, 16 Ph.D.s

HISTORY: Founded in 1979

FACILITIES: Four analytical laboratories--located in: Wokingham, UK; Geneva, Switzerland; and West Chester, Pa. Marketing offices in Manchester, U.K.; Freiburg, Bonn and Munich, Germany; and South Korea

STOCK-FINANCIAL HISTORY: Privately held

SUBSIDIARIES/DIVISIONS: M-Scan SA 12, Chemin des Aulx 1228 Plan-les-Ouates Geneva, Switzerland Phone: + 41 (0)22 794 83 74 Fax: + 41 (0)22 794 83 55 E-mail: [email protected]

M-Scan Inc. Dr. Mark Rogers 606 Brandywine Parkway West Chester, PA 19380 Phone: (610) 696-8210 Fax: (610) 696-8370 E-mail: [email protected]

RESEARCH & DEVELOPMENT: Use of mass spectrometry for the structure and sequence analysis of recombinant protein products and analysis of posttranslational modifications

MSE Technology Applications Inc.

P.O. Box 4078, 200 Technology Way Butte MT 59701, US Phone: (406) 494-7100; Fax: (406) 494-7230 Web: www.mse-ta.com E-mail: [email protected]

KEY PERSONNEL: Donald R. Peoples; President Jeff Ruffner; Exec. VP and General Manager Neal Egan; Head, Business Development

EMPLOYEES: 200+ employees

HISTORY: Founded in 1974

FACILITIES: Butte, Mont.--Corporate office, 53-acre Mike Mansfield Advanced Technology Center, Montana Information Technology Enterprise Center, welding and fabrication center STOCK-FINANCIAL HISTORY: Privately held

SUBSIDIARY OF: Montana Economic Revitalization and Development Institute

BUSINESS STRATEGY: MSE Technology Applications Inc. is a diversified research and engineering firm. We are a small business headquartered in Butte, Montana, with offices in Washington, Idaho, North Carolina, South Carolina, Washington, D.C., and West Virginia. MSE scientists and engineers are internationally recognized as the very best in their fields--developing and deploying some of the nation’s most sophisticated cutting-edge technology.

Business Areas:

Remediation Services--MSE provides services to private commercial entities and government agencies for municipal and industrial water treatment, biotechnologies, biological barriers, biological remediation, enhanced oil recovery, and counter chemical and biological terrorism.

Site Cleanup and Closure Support--MSE develops, tests, evaluates and deploys innovative technology to address the environmental issues surrounding site closures across the United States. We also identify and develop promising technologies to address the Department of Energy's site waste problems (such as transuranic mixed waste problems). More than 80 projects, at 26 facilities in 21 states, have been completed or are underway, resulting in significant operational cost savings.

Waste Treatment Technology--The Waste Treatment Technology area provides a full range of treatment services to customers including plasma services, facilities and products. We develop and deploy technologies to resolve Department of Energy and Department of Defense waste problems.

Facility Modernization and Sustainability--MSE supports infrastructure modernization at troop-based facilities by providing engineering solutions to plant processes. Specifically, modernizing and increasing the efficiency of outdated processes at various ammunition and troop installations around the Army complex. This group’s real strength is providing process modifications through instrumentation and control system modernization as well as chemical and materials handling improvements.

Advanced Energy and Aerospace Programs--MSE is conducting cutting edge research for advanced energy and aerospace technology development. Projects have the potential for breakthroughs in aerospace technology and could reduce the cost of commercial and military space operations. MSE is developing an ultrahigh-pressure test system to provide ground testing for aerospace technologies that are crucial to development of the world’s first hypersonic wind tunnel.

Plasma Services--MSE is a world leader in the field of plasma technology for waste material treatment and is currently deploying two systems for the U.S. Army in Nevada and West Virginia.

Mine Waste Technology Program--MSE demonstrates innovative groundwater remediation technologies in Montana, South Dakota, Nevada, California, Minnesota, Missouri, Utah and Colorado to advance the development of engineering solutions to national environmental issues resulting from mining.

Information Technology Services--MSE’s Montana Information Technology Enterprise Center is a complete data center, provides a strategically isolated location, redundant power and fire protection, OCx capacity, triple levels of security and environmental controls. MSE provides contingency planning and implementation, disaster recovery, online data storage/ warehousing/ vaulting, parallel computing, telecommunications, project management, and web services and development.

RESEARCH & DEVELOPMENT: Heavy metals in soils and water Thermal spray technology Lightweight materials technology Plasma arc treatment technology Biological remediation Counter chemical and biological terrorism Aerospace technology

Nanogen Inc.

10398 Pacific Center Court San Diego CA 92121, US Phone: (858) 410-4600; Fax: (858) 410-4952 Toll-free phone: (877) 626-6436 Web: www.nanogen.com E-mail: [email protected]

KEY PERSONNEL: Howard C. Birndorf; Chairman and CEO David Ludvigson; President and COO Robert Saltmarsh; CFO Graham Lidgard, Ph.D.; Sr. VP, R&D Walt Mahoney; VP, R&D Merl F. Hoekstra; VP, Business Development

EMPLOYEES: 235 employees

HISTORY: Founded in 1993 Acquired SynX Pharma Inc. (4/04) Merged with Epoch Biosciences Inc. (12/04) To acquire Spectral Diagnostic Inc.’s rapid cardiac immunoassay test business (as of 12/05) To acquire the diagnostics division of Amplimedical SpA (as of 4/06)

FACILITIES: 51,000 sq. ft. in San Diego, Calif. 30,000 sq. ft. in Bothell, Wash. 50,000 sq. ft. in Toronto, Canada 2,600 sq. ft. in Helmond, Netherlands

STOCK-FINANCIAL HISTORY: NASDAQ--NGEN IPO--3.9M shares at $11/share, $42.9M (4/98) Secondary offering--$80M (11/00) Revenue $12.544M (YE 05) compared to $5.374M (YE 04) Net loss <$96.494M> (YE 05) compared to <$38.907M> (YE 04) Loss per share <$1.95/share> (YE 05) compared to <$1.21/share> (YE 04) Average shares outstanding 49.585M (YE 05) compared to 32.203M (YE 04) Total assets $98.081M (YE 05) compared to $176.024M (YE 04)

PRIVATE PLACEMENTS: Raised $26.2M through private placement of Series C preferred stock (3/97) Raised $20M through private placement of 6.8M shares and 1M warrants (9/05)

SUBSIDIARIES/DIVISIONS: Molecular Research Products division: 21720 23rd Drive S.E., No. 150 Bothell, WA 98021 Phone: (800) 562-5544 Fax: (425) 482-5550 E-mail: [email protected]

Point of Care Diagnostics division: 1 Marmac Drive Toronto , Ontario M9W 1E7 Canada Phone: (877) 246-7593 Fax: (416) 798-3447 E-mail: [email protected]

Nanogen Europe BV: Steenovenweg 3 5708 HN Helmond Netherlands Phone: +31 (0)492-507-160 Fax: +31 (0)492-507-179

PRINCIPAL INVESTORS: Birndorf Biotechnology Development Enterprise Partners InterWest Partners Kleiner, Perkins, Caufield and Byers New Leaf Venture Partners

INVESTMENTS: Jurilab Ltd.

FINANCIAL INFORMATION: Completed $3.5M round of venture capital financing (2/94) Completed $9.5M round of venture capital financing (10/95) Received $2M two-year grant from U.S. Department of Commerce (7/95) Received $500K grant from Bude Technology Group (4/96) Received $250K grant from the State of California Defense Conversion Matching Grant (6/96)